Literature DB >> 15097933

Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.

Adam C Esser1, Andy Abril, Scott Fayne, John A Doyle.   

Abstract

Infliximab, a chimeric mouse-human monoclonal antibody, blocks the action of tumor necrosis factor-alpha and is a highly effective treatment for several inflammatory disorders, including inflammatory bowel disease and rheumatoid arthritis. Although safety data are encouraging, immunosuppressive sequelae may result. We report the acute development of multiple squamous cell carcinomas and keratoacanthomas in a patient receiving infliximab for rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15097933     DOI： 10.1016/j.jaad.2003.11.044

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  15 in total

1.  A practical approach to monitoring patients on biological agents for the treatment of psoriasis.

Authors:  Jason J Emer; Amylynne Frankel; Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

Review 2.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

3.  Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report.

Authors:  Ismail Simsek; Salih Pay; Ayhan Dinc; Hakan Erdem; Bulent Kurt
Journal:  Clin Rheumatol       Date:  2006-10-24       Impact factor: 2.980

4.  Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab.

Authors:  Shawn C Chen; Oscar W Cummings; Michael P Hartley; Carol A Filomena; Won Kyoo Cho
Journal:  Dig Dis Sci       Date:  2006-05-03       Impact factor: 3.199

5.  Effects of infliximab on sister chromatid exchanges and chromosomal aberration in patients with rheumatoid arthritis.

Authors:  M Atteritano; S Mazzaferro; S Mantuano; G L Bagnato; G F Bagnato
Journal:  Cytotechnology       Date:  2015-05-27       Impact factor: 2.058

6.  Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.

Authors:  Millie D Long; Hans H Herfarth; Clare A Pipkin; Carol Q Porter; Robert S Sandler; Michael D Kappelman
Journal:  Clin Gastroenterol Hepatol       Date:  2010-01-16       Impact factor: 11.382

Review 7.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

8.  TNF-α inhibitors: are they carcinogenic?

Authors:  Girindra Raval; Paulette Mehta
Journal:  Drug Healthc Patient Saf       Date:  2010-12-06

Review 9.  Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.

Authors:  George Kouklakis; Eleni I Efremidou; Michael Pitiakoudis; Nikolaos Liratzopoulos; Alexandros Ch Polychronidis
Journal:  Drug Des Devel Ther       Date:  2013-03-27       Impact factor: 4.162

10.  The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.

Authors:  Louise K Mercer; Adele C Green; James B Galloway; Rebecca Davies; Mark Lunt; William G Dixon; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich
Journal:  Ann Rheum Dis       Date:  2012-01-12       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.